Further investigations using clinical specimens are warranted to explore the clinical usefulness of SA14 as a predictive biomarker for anti‐PD‐1/PD‐L1‐based anticancer therapy, the detailed mechanisms underlying the regulation of SA14 expression, the potential side effects when combining chemotherapeutic agents with anti‐PD‐L1 in patients with CRC, and the efficacy of various pharmacological approaches that modulate SA14 expression as anticancer regimens. The gene discussed is PDCD1; the disease is colorectal carcinoma.